June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Novel CCR3 antagonists are effective mono- and combination inhibitors of CNV growth and vascular permeability
Author Affiliations & Notes
  • Yin Shan Eric Ng
    Vascular Biology, The Schepens Eye Research Institute, Boston, MA
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Norihiro Nagai
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Meihua Ju
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Kanako Izumi-Nagai
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Scott Robbie
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • James W B Bainbridge
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • Achim H Krauss
    Ophthiris Discovery Performance, GlaxoSmithKline, King of Prussia, PA
  • David C Gale
    Ophthiris Discovery Performance, GlaxoSmithKline, Stevenage, United Kingdom
  • Peter S Adamson
    Ophthiris Discovery Performance, GlaxoSmithKline, Stevenage, United Kingdom
  • David Shima
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Yin Shan Eric Ng, GlaxoSmithKline (F); Norihiro Nagai, None; Meihua Ju, GSK (F); Kanako Izumi-Nagai, None; Scott Robbie, None; James Bainbridge, None; Achim Krauss, GlaxoSmithKline (E); David Gale, GSK (E); Peter Adamson, GlaxoSmithKline (E); David Shima, GlaxoSmithKline (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2290. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yin Shan Eric Ng, Norihiro Nagai, Meihua Ju, Kanako Izumi-Nagai, Scott Robbie, James W B Bainbridge, Achim H Krauss, David C Gale, Peter S Adamson, David Shima; Novel CCR3 antagonists are effective mono- and combination inhibitors of CNV growth and vascular permeability. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2290.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We explored the functional role of CCR3 in laser-induced- and spontaneous choroidal neovascularisation (CNV) in mouse and non-human primate laser-CNV models.

Methods: Models of spontaneous CNV (JR5558 mice) and laser-induced CNV (mice and primates) were used to assess the therapeutic efficacy of novel C-C chemokine receptor 3 (CCR3) antagonists GW766994 and GW782415. CCR3 and ligands expression was analyzed by immunohistochemistry (IHC), real-time PCR and ELISA. GW766994 and GW782415 were administered by systemic, intraocular and topical routes. Neutralizing antibodies to vascular endothelial growth factor receptor 2 (VEGFR2), CCR3 and ligands were administered by intravitreal injection (IVT), and also systemic injection for anti-VEGFR2. CNV number, area and permeability were evaluated by fundus fluorescein angiography (FFA) and IHC in the mouse, and by FFA in the primate.

Results: Oral dosing with GW766994 reduced development of laser-induced CNV in the mouse model in a dose-dependent fashion. In the JR5558 mice, both number and size of spontaneous CNV lesions were significantly reduced in a dose-dependent manner following systemic exposure to GW766994, and CCR3 expression was associated with CNV. Increased expression of CCR3 ligands was localized to CNV-associated macrophages and from isolated retinal pigment epithelium/choroid complex. IVT antibodies against VEGFR2, CCR3, eotaxin-1 and eotaxin-2 all significantly reduced CNV area and lesion number. Combination treatment with anti-VEGFR2 and GW766994 inhibited CNV leakiness and resulted in an additive reduction in CNV area. Topical CCR3 antagonist was effective in inhibiting spontaneous CNV. Importantly, strong systemic effects on CNV inhibition from topical dosing of CCR3 antagonist and IVT anti-CCR3 antibody were detected. In the primate, oral dosing of GW782415 resulted in a significant suppression of grade IV CNV lesions at 16, 24 and 30 days following laser photocoagulation, whereas neither topical nor intravitreal dosing yielded an efficacy response.

Conclusions: We have demonstrated a direct functional role for CCR3 in the development of CNV, and oral systemic administration of CCR3 antagonists can reduce development of CNV in both mice and primates. Our data suggest that CCR3 signaling may be an attractive therapeutic target for neovascular AMD, and that it is at least partly distinct from the VEGF signaling pathway.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×